A Phase 4 interventional study of Sodium ferric gluconate, ferrous sulfate, standard of care in Anemia, sponsored by Watson Pharmaceuticals. Completed at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-02.
Sponsored by Watson Pharmaceuticals · Phase 4, Interventional, and Treatment
This study evaluates the safety and efficacy of Ferrlecit® (ferric gluconate; a form of intravenous iron) or ferrous sulfate (a form of oral iron) in improving the response to epoetin alfa among anemic cancer patients receiving chemotherapy.
1,733 studies on the registry are indexed under Anemia; 246 are open to participants now.
This study's enrollment of 180 is above the median of 94 across 1,291 interventional studies indexed under Anemia.
Browse Anemia studies →Watson Pharmaceuticals is the lead sponsor of 30 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Change in hemoglobin
Change in various iron indices
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Watson Pharmaceuticals